Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer
Journal of Clinical Laboratory Analysis · 2024
DOI: 10.1002/jcla.25124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2024. Verfasst von Ning Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Cancer Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hos…. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Machine Learning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Cancer Hospital Climb Plan, Hunan Provincial Natural Scientific Foundation, the China Anti-Cancer Association HER2 target Chinese Research Fund.
Abstract (Originalsprache)
Background
HER2‐positive breast cancer (BC), a highly aggressive malignancy, has been treated with the targeted therapy inetetamab for metastatic cases. Inetetamab (Cipterbin) is a recently approved targeted therapy for HER2‐positive metastatic BC, significantly prolonging patients' survival. Currently, there is no established biomarker to reliably predict or assess the therapeutic efficacy of inetetamab in BC patients.
Methods
This study harnesses the power of metabolomics and machine learning to uncover biomarkers for inetetamab in BC therapy. A total of 23 plasma samples from inetetamab‐treated BC patients were collected and stratified into responders and nonresponders. Ultra‐high‐performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry was utilized to analyze the metabolites in blood samples. A combination of univariate and multivariate statistical analyses was employed to identify these metabolites, and their biological functions were then ascertained by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Finally, machine learning algorithms were employed to screen responsive biomarkers from all differentially expressed metabolites.
Results
Our finding revealed 6889 unique metabolites that were detected. Pathways like retinol metabolism, fatty acid biosynthesis, and steroid hormone biosynthesis were enriched for differentially expressed metabolites. Notably, two key metabolites associated with inetetamab response in BC were identified: FAPy‐adenine and 2‐Pyrocatechuic acid. There was some negative correlation between progress‐free survival (PFS) and their kurtosis content.
Conclusions
In summary, the identification of these two significant differential metabolites holds promise as potential biomarkers for evaluating and predicting inetetamab treatment outcomes in BC, ultimately contributing to the diagnosis of the disease and the discovery of prognostic markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Cancer Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
- Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
- Department of Orthopaedics, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
ORCID-Profile: Quchang Ouyang
Förderung
- Hunan Cancer Hospital Climb Plan
- Hunan Provincial Natural Scientific Foundation
- the China Anti-Cancer Association HER2 target Chinese Research Fund
Zitieren
APA
Xie, N., Liao, D., Liu, B., Zhang, J., Liu, L., Huang, G., & Ouyang, Q. (2024). Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.25124
Vancouver
Xie N, Liao D, Liu B, Zhang J, Liu L, Huang G, et al. Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer. Journal of Clinical Laboratory Analysis. 2024. doi:10.1002/jcla.25124
BibTeX
@article{Xie2024,
author = {Xie, Ning and Liao, Dehua and Liu, Binliang and Zhang, Jiwen and Liu, Liping and Huang, Gang and Ouyang, Quchang},
title = {Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer},
journal = {Journal of Clinical Laboratory Analysis},
year = {2024},
doi = {10.1002/jcla.25124}
}
EUVIMED